Merdury signs MOU with Health2Sync to conduct trial of Merdury’s StackDose technology intended for usage in GLP-1 (semaglutide) medication

Posted on by

TAIPEI, July 25, 2024 /PRNewswire/ — Merdury Biopharmaceutical Corporation (Merdury) (Taipei Exchange Stock Code: 6932) announced today that it has signed a Memorandum of Understanding (MOU) with Health2Sync, Asia’s largest chronic disease management platform. In this collaboration, the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.